Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AEOLUS PHARMACEUTICALS, INC.

SummaryNewsCompanyFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Aeolus Pharmaceuticals, Inc. : Aeolus Announces Commencement of Assignment for the Benefit of Creditors

03/23/2018 | 03:31pm EST

MISSION VIEJO, CA / ACCESSWIRE / March 23, 2018 / Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), announced today that it has commenced an out-of-court liquidation conducted by an Assignment for the Benefit of Creditors pursuant to Delaware law. The Board of Directors has authorized Aeolus to enter into a General Assignment agreement with John D. McLaughlin, Jr., Esq. as the Assignee of all of Aeolus' remaining assets. To this effect, Aeolus has transferred its assets to the Assignee whose contractual duty is to liquidate these assets and distribute any proceeds to creditors. If the recovered value of these assets is not greater than the liabilities of Aeolus, there will not be any residual value for stockholders. In connection with the Assignment, Aeolus will discontinue the development of its compounds and all other operations.

About Aeolus Pharmaceuticals

Aeolus Pharmaceuticals, based in Mission Viejo, CA, has been engaged in the development of medical countermeasures for radiological, chemical and biological threats under programs previously supported by funding from the United States government.

Forward-Looking Statements

The statements in this press release that are not purely statements of historical fact are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements herein with respect to the Company's plans and the successful execution of the Company's current strategy. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.

Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' Annual Report on Form 10-K for the year ended September 30, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Contact:

John McManus
President and Chief Executive Officer
Aeolus Pharmaceuticals, Inc.
1-(949) 481-9820

SOURCE: Aeolus Pharmaceuticals, Inc.


ę Accesswire 2018
All news about AEOLUS PHARMACEUTICALS, INC.
2017Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the ..
CI
2017Aeolus Pharmaceuticals, Inc. Announces Fast Track Designation Granted to AEOL 10150 for..
CI
2017Aeolus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Se..
CI
2017Aeolus Pharmaceuticals : Receives BARDA Decision Regarding Additional Options for Lung ARS..
PU
2017Aeolus Pharmaceuticals, Inc. Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Vo..
CI
2017Aeolus Pharmaceuticals : Announces First Quarter 2017 Financial Results
PU
2016Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quar..
CI
2016Aeolus Pharmaceuticals : Announces Publication of Additional Data Demonstrating Efficacy o..
PU
2016Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Thi..
CI
2016Stocknewsnow.com : Publishes New SNNLive Video Interview with Aeolus Pharmaceuticals, Inc...
PR
More news
Managers and Directors
John L. McManus President & Chief Executive Officer
David Charles Cavalier Chairman, Chief Operating & Financial Officer
Amit D. Kumar Independent Director
Chris A. Rallis Independent Director
John Mitchell Farah Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AEOLUS PHARMACEUTICALS, INC.0
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-20.82%22 727